Shares of Ginkgo Bioworks are up 15% or 26c at $1.99 per share in pre-market trading after the company announced a collaboration deal with Pfizer focused on the discovery of RNA-based drug candidates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DNA:
- Unusually active option classes on open September 27th
- Ginkgo Bioworks announces multi-target RNA discovery collaboration with Pfizer
- Ginkgo Bioworks, Madagascar enter MoU to develop new biosecurity capabilities
- Cathie Wood’s ARK Investment bought 1.3M shares of Ginkgo Bioworks today
- Cathie Wood’s ARK Investment bought 2.17M shares of Ginkgo Bioworks today